MagnetisMM-4
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
What's the purpose of the trial?
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Accepting patients
Participating Centers
There are 6 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Elranatamab is a B-Cell Maturation Antigen (BCMA) CD-3 bispecific antibody being tested in multiple myeloma
- Nirogacestat is a selective, reversible, non-competitive gamma-secretase inhibitor drug that is expected to increase the anti-tumor effectiveness of drugs like elranatamab
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.